Close Menu

NEW YORK (360Dx) – Biocept said in a regulatory filing that it anticipates net proceed of $5.4 million for an offering of its securities, down from $9.1 million that the firm estimated last week.

In an amended prospectus filed with the US Securities and Exchange Commission today, the company said that it now plans to offer about 5.3 million shares of its common stock as well as warrants to purchase 5.3 million shares of its stock at an assumed combined public offering price of $1.14 per share and related warrant.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.